GlassScriptPhysician profile
Ravindra Kumar Mehta
NPI 1063599835
$18,477.06
in general payments reported to CMS, 2019-2025
25 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,732 · 2020: $1,126 · 2021: $1,551 · 2022: $1,543 · 2023: $2,277 · 2024: $2,284 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,414 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,413.78 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $6,866.01 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,820.57 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,599.89 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $1,487.91 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,206.60 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Alkermes, INC. | $1,085.52 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $996.21 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $556.19 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $523.84 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $456.96 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $353.49 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $301.57 | 2021-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $270.63 | 2019-2022 | |
| Corium, LLC | $194.68 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $171.45 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $130.99 | 2022-2024 | Quviviq |
| Aurinia Pharma U.S., INC. | $105.60 | 2024 | Lupkynis |
| Almatica Pharma LLC | $76.76 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Abbvie INC. | $68.28 | 2022 | |
| Indivior INC. | $66.96 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $53.62 | 2019 | |
| Collegium Pharmaceutical, INC. | $38.50 | 2025 | Jornay Pm |
| Eisai INC. | $18.76 | 2021 | |
| Allergan, INC. | $13.26 | 2020 | |
| Merck Sharp & Dohme LLC | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravindra Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.